The University of Chicago Header Logo

Search Result Details

Back to Search Results
This page shows the details of why an item matched the keywords from your search.
Search Results
Jakubowiak, Andrzej
One or more keywords matched the following items that are connected to Jakubowiak, Andrzej
Item TypeName
Academic Article Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition.
Academic Article An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma.
Academic Article Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients.
Academic Article Current strategies for treatment of relapsed/refractory multiple myeloma.
Academic Article Evolution of carfilzomib dose and schedule in patients with multiple myeloma: a historical overview.
Academic Article Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients.
Academic Article Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma.
Academic Article Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10-Dependent Apoptosis by Carfilzomib and Selinexor.
Academic Article Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells.
Academic Article A Phase Ib/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenström Macroglobulinemia.
Academic Article Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma.
Academic Article Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up.
Academic Article Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study.
Academic Article Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice.
Academic Article Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study.
Concept Proteasome Inhibitors
Search Criteria
  • Proteasome Endopeptidase Complex